Medivisor Inc. Signs Revenue Sharing Agreement With PanGenex
Medivisor Inc. (PINKSHEETS: MVSR) announced today that it has signed a revenue sharing agreement for the marketing and sale of LIPIDEME(TM) with PanGenex Corporation (PINKSHEETS: PGXC). PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. PanGenex focuses specifically on the cardiovascular health segment.
The terms of the Agreement call for the companies to pool collective resources for the marketing and sale of LIPIDEME(TM), a synergistic blend of ingredients designed to lower cholesterol four ways. The American Heart Association’s scouting report on coronary artery disease identifies high cholesterol as one of the most important risk factors for cardiovascular health. The AHA estimates that nearly 140 million Americans have either borderline-high or high cholesterol, as determined by a blood test called a lipid panel. In 2003, approximately 22 million people took a medication to try to lower their cholesterol. LIPIDEME is positioned as an all-natural product to address high cholesterol from a dietary and genetic standpoint.
LIPIDEME is formulated with pharmaceutical grade fish oil that is over 86% pure Omega-3s; the highest content available without a prescription for heart, mental, joint and skin health. The Omega-3s in LIPIDEME are molecularly distilled and tested to ensure that there are no detectable levels of Mercury, PCBs, or other toxins or heavy metals. In addition to the purity of the Omega-3s, PanGenex has formulated LIPIDEME to include Phytosterols, a plant sterol that inhibits the absorption of cholesterol in the digestive system, tocotrienols, a form of Vitamin E which inhibits the formation of the enzymes that create cholesterol in the liver and CoQ10, a powerful antioxidant for muscle energy, specifically cardiac muscle.
“We are excited to partner with Medivisor for assistance in bringing LIPIDEME to the market. We also believe that this collaboration will allow us to open the product to international expansion and provide our practitioners with a valuable communication resource in taking advantage of the Medivisor network,” stated Jeff Roman, President and CEO of PanGenex Corporation.
Medivisor Inc. CEO Dino Luzzi added, “We are very pleased that PanGenex has selected Medivisor to market and sell LIPIDIME. Under this agreement our main objective will be to contribute to the sales growth of LIPIDIME through both US and International distribution channels. This will also drive further revenue and profits for Medivisor.”
About Medivisor Inc.:
Medivisor Inc. is a rapidly growing developer of next-generation focus driven marketing tools. The company is dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets and beyond. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of its clients. http://www.medivisor.com
About PanGenex Corporation:
PanGenex is a publicly traded corporation (PINKSHEETS: PGXC) and pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Additionally, words such as “seek,”"intend,”"believe,”"plan,”"estimate,”"expect,”"anticipate” and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Dino Luzzi CEO Medivisor Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 http://www.medivisor.com
SOURCE: Medivisor Inc.